New York State Common Retirement Fund Raises Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

New York State Common Retirement Fund grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 16.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 131,820 shares of the medical research company's stock after acquiring an additional 18,894 shares during the period. New York State Common Retirement Fund owned about 0.27% of Charles River Laboratories International worth $19,842,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Rothschild Investment LLC lifted its stake in Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after purchasing an additional 144 shares in the last quarter. Optiver Holding B.V. purchased a new stake in shares of Charles River Laboratories International in the fourth quarter worth about $37,000. HM Payson & Co. bought a new position in Charles River Laboratories International during the first quarter valued at approximately $31,000. GeoWealth Management LLC grew its holdings in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after buying an additional 190 shares in the last quarter. Finally, Pilgrim Partners Asia Pte Ltd bought a new stake in Charles River Laboratories International in the 4th quarter worth approximately $48,000. Institutional investors own 98.91% of the company's stock.

Insider Activity

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of Charles River Laboratories International stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president directly owned 19,513 shares of the company's stock, valued at $2,837,385.33. The trade was a 2.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on CRL. Wall Street Zen lowered shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Saturday, July 5th. Mizuho dropped their price objective on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. Citigroup upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Evercore ISI increased their price target on shares of Charles River Laboratories International from $170.00 to $180.00 and gave the company an "outperform" rating in a report on Wednesday, July 9th. Finally, TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective on the stock in a research note on Wednesday, May 14th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $174.54.

Charles River Laboratories International Trading Up 0.4%

Shares of NYSE:CRL traded up $0.55 on Wednesday, hitting $154.97. 526,556 shares of the company's stock were exchanged, compared to its average volume of 1,030,790. The stock has a market capitalization of $7.61 billion, a price-to-earnings ratio of -238.42, a price-to-earnings-growth ratio of 5.35 and a beta of 1.49. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.43 and a quick ratio of 1.16. The business's 50 day simple moving average is $146.43 and its two-hundred day simple moving average is $151.17.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter last year, the business posted $2.27 EPS. Analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).